Abstract: This invention provides vectors, improved host cells and improved methods for producing a heterologous protein by culturing an improved eucaryotic host cell of this invention transformed or transfected with a vector capable of directing the expression of the heterologous protein. The preferred improved host cell of this invention is a mammalian host cell containing and capable of expressing an anti-sense GRP78 DNA sequence.

Abstract: A homogeneously modified protein is provided having one or more selected naturally occurring lysine residues replaced by a suitable amino acid, or having one or more lysine residues substituted for other amino acids or inserted into a polypeptide sequence, leaving selected lysine residues having .epsilon.-amino groups in the protein and coupling amine reactive compounds to selected lysine residues. Methods for producing the selected homogeneously modified proteins and pharmaceutical compositions containing such proteins are provided.

Abstract: This invention relates to novel proteins useful for enhancing pulmonary surfactant activity, methods for obtaining said proteins and compositions containing one or more of the proteins. The proteins of this invention include the following:1. A protein characterized by a molecular weight of about 35 kd and by being encoded for by the DNA sequence depicted in Table 1.2. A protein characterized by a molecular weight of about 35 kd and by being encoded for by the DNA sequence depicted in Table 2.3. A protein encoded for by a portion of the DNA sequence depicted in Table 6 and characterized by a molecular weight of about 5.5-9 kd; and4. A protein characterized by a molecular weight of about 5.5-9 kd and an amino acid composition as set forth in Table 4.

Abstract: A biocatalytic method for producing a desired amino acid is disclosed. The method involves contacting a 2-ketoacid corresponding to the desired amino acid with lactic acid, aspartic acid and ammonia, or salts thereof, in the presence of:(a) one or more transaminase enzymes capable of catalyzing the conversion of the 2-ketoacid and L-aspartic acid to the desired amino acid and oxaloacetic acid;(b) a malate-lactate transhydrogenase enzyme capable of catalyzing the conversion of lactic acid and oxaloacetic acid to pyruvic acid and malic acid;(c) a fumarase enzyme capable of catalyzing the conversion of malic acid to fumaric acid; and(d) an aspartate-ammonia lyase enzyme capable of catalyzing the conversion of fumaric acid and ammonia to aspartic acid.

Abstract: A process for producing a novel protein, CSF-69, is provided. The protein is capable of stimulating proliferation of monocytic lineage types cells in vitro assays. A novel DNA sequence codes on expression for CSF-69.

Abstract: Human and bovine bone inductive factors are provided. Such factors may be produced by recombinant techniques and be useful in the treatment of bone defects.

Abstract: A novel family of primate IL-3-like polypeptides is provided via recombinant techniques.

Abstract: A novel family of primate CSF-1-like polypeptides is provided via recombinant techniques.

Abstract: Novel procoagulant proteins are disclosed which comprise the amino acid sequence:A-X-Bwherein region A represents the polypeptide sequence Ala-20 through Arg-759 substantially as shown in Table 1; region B represents the polypeptide sequence Ser-1709 through Tyr-2351 substantially as shown in Table 1; and region X represents a polypeptide sequence comprising up to 949 amino acids substantially duplicative of sequences of amino acids within the sequence SER-760 through Arg-1708 of Table 1, wherein the amino terminus of X is covalently bonded through a peptide bond designated "-" to the carboxy terminus of A, and the carboxy terminus of X is likewise bonded to the amino terminus of B. Methods of making such proteins and their use in pharmaceutical preparations is also disclosed.

Abstract: A storage stable single phase aqueous composition is provided which is useful in isolatin nucleic acids from cell or virus cultures.

Abstract: A new improved glycoprotein having erythropoietin-type activity is disclosed. The substrate is characterized by amino acid sequence substantially identical to the amino acid sequence of native human erythropoietin wherein the methionine-54 is replaced with leucine. DNA encoding for the EPO-substance and expression vectors incorporating the same are disclosed. Therapeutic compositions and methods for treatment of anemic conditions are described.

Abstract: A method for isolating and purifying nucleic acids from eukaryotic and prokaryotic cell cultures or viral cell cultures.

Abstract: This invention relates to a process for producing a desired alpha-amino acid, AA.sub.d, or a derivative thereof. The process comprises:(a) reacting a first alpha-amino acid, AA.sub.NH.sbsb.2 ; a first alpha-keto acid, KA.sub.t ; a second alpha-keto acid, KA.sub.pre ; a first transaminase enzyme and a second transaminase enzyme to produce (i) the desired alpha-amino acid, AA.sub.d and (ii) a third alpha-keto acid, KA.sub.prod ; and(b) removing KA.sub.prod from the other keto acids, amino acids and enzymes wherein AA.sub.d and KA.sub.pre, AA.sub.t and KA.sub.t, and AA.sub.NH.sbsb.2 and KA.sub.prod are interconvertible, respectively, by amino group transfer. The first transaminase efficiently catalyzes reaction (i), but not reaction (ii) and the second transaminase efficiently catalyzes reaction (ii) but not reaction (i):AA.sub.NH.sbsb.2 +KA.sub.t .revreaction.AA.sub.t +KA.sub.prod (i)AA.sub.t +KA.sub.pre .revreaction.AA.sub.d +KA.sub.t (ii)In one embodiment KA.sub.

Abstract: This invention concerns a method for producing a heterologous protein in a bacterial host cell such that the protein is exported from the host cell into the culture medium. The method involves culturing in a bacterial culture medium a genetically engineered bacterial strain containing a fusion DNA sequence comprising a first nucleotide sequence encoding at least an N-terminal portion of a flagellin protein and a second nucleotide sequence encoding the heterologous protein. The first nucleotide sequence is linked via its 3' terminus to the 5' terminus of the second nucleotide sequence, and the fusion DNA sequence is itself linked to an expression control sequence.

Abstract: High yields of active Factor IX are produced by culturing a CHO cell line transfected with chromosomally-integrated Factor IX cDNA in medium to which vitamin K is added.

Abstract: A diagnostic reagent is disclosed containing a complex of a probe polynucleotide (P) bound via purine/pyrimidine hydrogen bonding to a labeled polynucleotide (L). The probe (P) contains a target binding region (TBR) capable of binding to a target nucleotide sequence (G) of a biological sample. A method is disclosed in which contact with a sample containing the target nucleotide sequence (G) causes binding, initially between G and a single-stranded portion (IBR) of the target binding region (TBR). Thereafter the labeled polynucleotide (L) is displaced from the complex by branch migration of (G) into the (P)/(L) binding region. A volume excluding polymeric agent such as poly(ethylene oxide) (PEO or PEG) or other polyethers enhances the rate of appearance of displaced labeled polynucleotide. Determination of displaced labeled polynucleotide (L) gives a value which is a function of the presence and concentration of target nucleotide sequence (G) in the sample.

Abstract: A diagnostic reagent is disclosed containing a complex of a probe polynucleotide (P) bound via purine/pyrimidine hydrogen bonding to a labeled polynucleotide (L). The probe (P) contains a target binding region (TBR) capable of binding to a target nucleotide sequence (G) of a biological sample. A method is disclosed in which contact with a sample containing the target nucleotide sequence (G) causes binding, initially between G and a single-stranded portion (IBR) of the target binding region (TBR). Thereafter the labeled polynucleotide (L) is displaced from the complex by branch migration of (G) into the (P)/(L) binding region. Determination of displaced labeled polynucleotide (L) gives a value which is a function of the presence and concentration of target nucleotide sequence (G) in the sample.

Abstract: The mRNA of a distinct human Interleukin-2 concentrated from a plasma source lead to the production and cloning of its cDNA and the elucidation of its sequence and that of the mature protein. Transfer vectors for production of such Interleukin-2 are disclosed along with useful intermediate expression products.

Abstract: The protein having factor VIII:C procoagulant activity has been produced by culturing a cell transformed with a recombinant expression vector encoding the gene for that activity.

Abstract: A method for determining the presence and amount of a predetermined target nucleotide sequence in a biological sample is provided. The method employs a reagent complex which consists of a labeled probe polynucleotide having a target binding region and a second polynucleotide bound to the labeled probe in a second polynucleotide binding region thereof. The second binding region is at least partially coextensive with the target binding region. This reagent complex is contacted with a sample under conditions in which the target sequence binds to the labeled probe, displacing the second polynucleotide. Labeled probe/target hybrids are separated from intact reagent complexes and the presence and amount of these hybrids are determined.